Investors Watch List: The Coca-Cola Company (NYSE:KO), Corindus Vascular Robotics Inc. (NYSEMKT:CVRS), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), QTS Realty Trust, Inc.

Utter confusion unfolded on Coca-Cola Company (NYSE:KO)’s page on a Russian social network after the company sent greetings bearing an erroneous map of Russia, later replacing it with an image including Crimea, before erasing it altogether. The company first released the map minus Crimea, the Kuril Islands and Kaliningrad on its page on Vkontakte (the Russian equivalent of Facebook), on December 30, ahead of New Year’s celebrations across Russia.

The Coca-Cola Company (NYSE:KO) belongs to Consumer Goods sector. Its net profit margin is 15.20% and weekly performance is -3.18%. On last trading day company shares ended up at $42.32. The Coca-Cola Company (NYSE:KO) distance from 50-day simple moving average (SMA50) is -0.50%.

Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced the launch of a CorPath® robotic-assisted coronary intervention program at Massachusetts General Hospital (“MGH”) and the installation of its first CorPath System. Involvement in the robotic-assisted coronary intervention program will allow physicians at MGH to perform percutaneous coronary interventions (PCI) using the CorPath System while protected from radiation exposure in the system’s radiation-shielded control cockpit.

Corindus Vascular Robotics Inc. (NYSEMKT:CVRS) shares fell -5.79% in last trading session and ended the day at $2.93. CVRS Gross Margin is -64.00% and its return on assets is -63.40%. Corindus Vascular Robotics Inc. (NYSEMKT:CVRS) quarterly performance is -7.28%.

On 29 December, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced the closing of its previously-announced license and investment deal with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”). Oramed has sold 1,155,367 restricted shares of Common Stock at a price of $10.39 per Share, for an aggregate amount of $12 million. Oramed has additionally received approval from the Office of the Chief Scientist of the Israeli Ministry of Economy (“OCS”) for the out-licensing agreement with HTIT. Following receipt of the OCS’s approval, the out-licensing deal for ORMD-0801, a novel oral insulin capsule, has now closed.

On 06 January, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares fell -3.28% and was closed at $8.25. ORMP EPS growth in last 5 year was -1.60%. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) year to date (YTD) performance is -3.51%.

Deutsche Bank downgraded shares of QTS Realty Trust Inc (NYSE:QTS) from a buy rating to a hold rating in a research report released on Tuesday morning, The Fly reports. The firm currently has $47.00 price objective on the stock, down from their prior price objective of $48.00.

QTS Realty Trust, Inc. (NYSE:QTS) ended the last trading day at $44.13. Company weekly volatility is calculated as 2.10% and price to cash ratio as 169.71. QTS Realty Trust, Inc. (NYSE:QTS) showed a weekly performance of -2.48%.

On 4 January, Winthrop Realty Trust (NYSE:FUR) announced that the report in the San Antonio Business Journal that Winthrop has acquired a multi-family property in San Antonio, Texas is incorrect. As previously reported, Winthrop has adopted a plan of liquidation and is not seeking to acquire any additional assets. The report in the San Antonio Business Journal has since been withdrawn.

Winthrop Realty Trust (NYSE:FUR) shares moved up 0.38% in last trading session and ended the day at $13.06. FUR Gross Margin is 47.70% and its return on assets is 0.20%. Winthrop Realty Trust (NYSE:FUR) quarterly performance is -1.78%.

Leave a Reply

Your email address will not be published. Required fields are marked *